Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Proxinium awarded orphan drug status for recurrent head and neck cancer

Feb. 8, 2005

Xcyte withdraws phase II/III protocol in chronic lymphocytic leukemia

Feb. 7, 2005

1D09C3 enters phase I in B-cell lymphoma patients

Feb. 3, 2005

Preclinical targeting of B-cell lymphoma using the humanized monoclonal antibody CMC-544

Feb. 2, 2005

Northwest to begin phase III trial of DCVax-Prostate

Feb. 2, 2005

Tarvacin cleared to enter new phase I study

Feb. 1, 2005

Treatment begins in phase II study of HER-2 Protein AutoVac

Jan. 28, 2005

AMD-3100 phase III program opens enrollment

Jan. 28, 2005

Viventia completes enrollment in second phase I study of Proxinium

Jan. 28, 2005

Good safety profile reported for CEA-TRICOM vaccines in advanced cancer patients

Jan. 25, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
KBN-2201 reverses key features of Alzheimer’s in mice
BioWorld Science
Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.
In vivo click ADCs could address tumor heterogeneity
BioWorld
Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...